- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 26, 2025
Distillery Therapeutics
Inhibiting EPCR or HO-1 for retinal neovascularization
BioCentury | Jul 7, 2023
Discovery & Translation
Smaller gene editors, Resilience’s cell-free antibody discovery platform and more
BioCentury’s roundup of translational innovations
BioCentury | Jul 18, 2019
Distillery Therapeutics
Inhibition of BACH1 or the genes it controls for metastatic lung cancer
BioCentury | May 11, 2018
Clinical News
FDA committee votes against Mallinckrodt's jaundice candidate in newborns
BioCentury | Jan 28, 2016
Distillery Therapeutics
Therapeutics: Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; NRF2); heme oxygenase decycling 1 (HMOX1; HO-1; Hsp32)
BioCentury | Jun 18, 2015
Distillery Therapeutics
Therapeutics: Activating transcription factor 4 (ATF4); heme oxygenase decycling 1 (HMOX1; HO-1; Hsp32)
Items per page:
1 - 10 of 16